A new targeted treatment for triple-negative breast cancer
VDX-111: A novel targeted therapeutic for triple-negative breast cancer
This study is testing a new drug called VDX-111 to see how well it can treat triple-negative breast cancer while being gentle on healthy breast cells, aiming to offer a better option for patients facing this tough type of cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vona Oncology, LLC NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10885215 on NIH RePORTER |
What this research studies
This research focuses on developing VDX-111, a novel drug specifically designed to treat triple-negative breast cancer (TNBC), which is known for being particularly aggressive and resistant to existing therapies. The approach involves understanding how VDX-111 induces cell death in TNBC cells while sparing normal breast cells, making it a targeted treatment option. The research includes laboratory studies using TNBC cell lines and patient-derived tumor models to evaluate the drug's effectiveness and to identify potential resistance mechanisms. By targeting specific genes associated with TNBC, this research aims to provide a more effective treatment strategy for patients suffering from this challenging cancer type.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have limited treatment options.
Not a fit: Patients with non-triple-negative breast cancer or those who do not have breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and targeted treatment option for patients with triple-negative breast cancer.
How similar studies have performed: While targeted therapies for other cancer types have shown success, this approach for triple-negative breast cancer is relatively novel and untested.
Where this research is happening
Aurora, UNITED STATES
- Vona Oncology, LLC — Aurora, United States (Active)
Researchers
- Principal investigator: Lambert, Cherie — Vona Oncology, LLC
- Study coordinator: Lambert, Cherie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.